ABUS (STOCKS)
Arbutus Biopharma Corporation Common Stock
$4.370000
+0.220000 (+5.30%)
Prev close: $4.150000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Lindsay Androski
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $854.24M
- Employees
- 44
- P/E (TTM)
- -23.66
- P/B (TTM)
- 10.43
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
3
Strong Buy
5
Buy
1
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$-0.02 | $-0.04 | +0.0157 | +43.98% |
|
Sep 2025 (Q3)
|
$-0.04 | $-0.03 | -0.0084 | -26.58% |
|
Jun 2025 (Q2)
|
$0.01 | $-0.05 | +0.0585 | +120.62% |
|
Mar 2025 (Q1)
|
$-0.13 | $-0.11 | -0.0245 | -23.22% |
Financial Statements
| Revenues | $14.08M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $52.24M |
| Nonoperating Income/Loss | $4.66M |
| Operating Expenses | $52.24M |
| Research and Development | $25.24M |
| Other Operating Expenses | $27.00M |
| Operating Income/Loss | -$38.16M |
| Income/Loss From Continuing Operations After Tax | -$33.50M |
| Income/Loss From Continuing Operations Before Tax | $14.08M |
| Income Tax Expense/Benefit | $0.00 |
| Net Income/Loss | -$33.50M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$33.50M |
| Net Income/Loss Available To Common Stockholders, Basic | -$33.50M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$0.17 |
| Diluted Earnings Per Share | -$0.17 |
| Basic Average Shares | 191,599,600 |
| Diluted Average Shares | 191,599,600 |
| Assets | $94.62M |
| Current Assets | $94.46M |
| Cash | $91.50M |
| Other Current Assets | $2.96M |
| Noncurrent Assets | $162.00K |
| Fixed Assets | $32.00K |
| Other Non-current Assets | $130.00K |
| Liabilities | $18.04M |
| Current Liabilities | $6.01M |
| Noncurrent Liabilities | $12.04M |
| Long-term Debt | $0.00 |
| Equity | $76.58M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $76.58M |
| Liabilities And Equity | $94.62M |
| Net Cash Flow From Operating Activities | -$39.64M |
| Net Cash Flow From Operating Activities, Continuing | -$39.64M |
| Net Cash Flow From Investing Activities | $15.58M |
| Net Cash Flow From Investing Activities, Continuing | $15.58M |
| Net Cash Flow From Financing Activities | $5.72M |
| Net Cash Flow From Financing Activities, Continuing | $5.72M |
| Exchange Gains/Losses | $14.00K |
| Net Cash Flow | -$18.32M |
| Net Cash Flow, Continuing | -$18.34M |
| Comprehensive Income/Loss | -$33.46M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$33.46M |
| Other Comprehensive Income/Loss | -$33.46M |
| Other Comprehensive Income/Loss Attributable To Parent | $37.00K |